BVS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bioventus Inc (BVS) does not present a compelling buy opportunity for a beginner, long-term investor at this time. Despite positive analyst ratings and bullish technical indicators, the company's financial performance shows significant declines in net income and EPS, which raises concerns about its profitability. Additionally, there are no recent news catalysts or significant trading trends to support immediate action.
The technical indicators suggest a bullish trend with the MACD histogram positively expanding and moving averages showing a bullish alignment (SMA_5 > SMA_20 > SMA_200). However, the RSI of 79.754 is in the neutral zone, and the stock's price has recently declined by 1.42% in the regular market and 0.58% in post-market trading.
Analysts have issued positive ratings with price targets ranging from $13 to $16, citing strong Q4 results and a solid fiscal 2026 outlook. The company's gross margin has improved by 3.67% YoY.
There are no recent news catalysts or significant insider or hedge fund trading trends.
In Q4 2025, revenue increased by 2.77% YoY to $157.9M, but net income dropped drastically by -3902.84% YoY to $14.76M. EPS also fell by -2200.00% YoY to 0.21. Gross margin improved to 68.07%, up 3.67% YoY.
Analysts have a positive outlook on Bioventus with Outperform and Buy ratings. Price targets have been raised recently, with the highest being $16. Analysts cite strong Q4 results, better-than-expected fiscal 2026 guidance, and mid-to-high single-digit sales growth expectations.
